metformin has been researched along with deoxycytidine in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 19 (86.36) | 24.3611 |
| 2020's | 3 (13.64) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Feng, YH; Gully, C; Lee, MH; Velazquez-Torres, G; Yeung, SC | 1 |
| Ahmad, A; Ali, S; Azmi, AS; Banerjee, S; Bao, B; Kong, D; Li, Y; Sarkar, FH; Sarkar, SH; Thakur, S; Wang, Z | 1 |
| Funakoshi, A; Ikeda, N; Kawanami, T; Takiguchi, S | 1 |
| Cheng, G; Dwinell, MB; Kalyanaraman, B; McAllister, D; Tsai, S; Zielonka, J | 1 |
| Kaddis, N; Saif, MW | 1 |
| Baron, B; Kuramitsu, Y; Maehara, S; Maehara, Y; Nakamura, K; Wang, Y | 1 |
| Beeker, A; Kordes, S; Mathôt, RA; Pollak, MN; Punt, CJ; Richel, DJ; Weterman, MJ; Wilmink, JW; Zwinderman, AH | 1 |
| Chai, X; Chu, H; Gou, S; Meng, Y; Shi, P; Yang, X | 1 |
| Badary, O; El Wakeel, L; Elkholy, E; Saad, AS; Sayed, R | 1 |
| Balzano, G; Belli, C; Ceraulo, D; Cereda, S; Di Terlizzi, G; Doglioni, C; Dugnani, E; Falconi, M; Lampasona, V; Liberati, D; Maggiora, P; Nicoletti, R; Pasquale, V; Piemonti, L; Reni, M; Scavini, M; Sordi, V | 1 |
| Albert, AC; Bürtin, F; Graffunder, J; Jaster, R; Kumstel, S; Müller, S; Radecke, T; Schönrogge, M; Shih, HY; Vollmar, B; Zechner, D; Zhang, X | 1 |
| He, Z; Jia, Z; Shi, Y; Xu, C | 1 |
| Chen, K; Chen, X; Duan, W; Han, L; Jiang, Z; Lei, J; Li, J; Li, X; Ma, J; Ma, Q; Ma, Z; Sun, L; Wang, F; Wang, Z; Wu, E; Wu, Z; Xu, Q | 1 |
| Chang, H; Gao, HJ; Li, HG; Liu, FF; Lu, J; Ma, CQ; Ma, JB; Song, X; Zhou, X; Zhu, HQ | 1 |
| Darko, KO; He, C; Huang, Y; Liu, Z; Peng, M; Su, Q; Tao, T; Yang, X; Yin, T | 1 |
| Damelin, LH; Jivan, R; Mavri-Damelin, D; Mynhardt, C; Peres, J; Prince, S; Veale, RB | 1 |
| Cao, J; Chen, K; Cheng, L; Duan, W; Jiang, Z; Li, J; Ma, Q; Qian, W; Yan, B; Zhou, C | 1 |
| Kitagawa, Y; Suzuki, K; Suzuki, Y; Takeuchi, O | 1 |
| Chen, XD; Qiao, ZG; Tang, JM; Wu, XY; Yao, XM; Zhou, HY | 1 |
| Chen, X; Gao, M; Han, H; Hou, Y; Ji, J; Jin, Q; Kang, M; Zhang, P | 1 |
| Abrams, SL; Akula, SM; Candido, S; Cervello, M; Cocco, L; Duda, P; Falzone, L; Gizak, A; Libra, M; Martelli, AM; McCubrey, JA; Meher, AK; Montalto, G; Rakus, D; Ratti, S; Ruvolo, P; Steelman, LS | 1 |
| Balconi, F; Berardi, R; Cimbro, E; Donisi, C; Giampieri, R; Lai, E; Lupi, A; Murgia, S; Pecci, F; Persano, M; Pozzari, M; Pretta, A; Pusceddu, V; Puzzoni, M; Scartozzi, M; Spanu, D; Ziranu, P | 1 |
1 review(s) available for metformin and deoxycytidine
| Article | Year |
|---|---|
Combination of metformin with chemotherapeutic drugs via different molecular mechanisms.
Topics: Androgen Antagonists; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Deoxycytidine; Estrogen Receptor Modulators; Fluorouracil; Gemcitabine; Humans; Metformin; Methotrexate; Neoplasms; Paclitaxel; Tubulin Modulators | 2017 |
3 trial(s) available for metformin and deoxycytidine
| Article | Year |
|---|---|
Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial.
Topics: Academic Medical Centers; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Metformin; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Netherlands; Pancreatic Neoplasms; Quinazolines; Survival Analysis; Treatment Outcome | 2015 |
Metformin Addition to Chemotherapy in Stage IV Non-Small Cell Lung Cancer: an Open Label Randomized Controlled Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Metformin; Middle Aged; Nausea; Neoplasm Staging; Pilot Projects; Prospective Studies; Survival Rate; Treatment Outcome | 2015 |
(Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Metformin; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2016 |
18 other study(ies) available for metformin and deoxycytidine
| Article | Year |
|---|---|
The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Diabetes Mellitus, Type 2; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Glucose; Humans; Hypoglycemic Agents; Insulin; Metformin; Neoplasms; Pancreatic Neoplasms; Rosiglitazone; Thiazolidinediones | 2011 |
Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Hypoglycemic Agents; Metformin; Mice; Mice, SCID; MicroRNAs; Neoplasm Invasiveness; Neoplastic Stem Cells; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Polycomb Repressive Complex 2; Real-Time Polymerase Chain Reaction; RNA, Messenger; Transcription Factors; Tumor Stem Cell Assay | 2012 |
A humanized anti-IGF-1R monoclonal antibody (R1507) and/or metformin enhance gemcitabine-induced apoptosis in pancreatic cancer cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Metformin; Pancreatic Neoplasms; Receptor, IGF Type 1; Survivin; X-Linked Inhibitor of Apoptosis Protein | 2012 |
Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Celecoxib; Cell Culture Techniques; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Deoxyglucose; Doxorubicin; Energy Metabolism; Gemcitabine; Glycolysis; Humans; Hydrogen; Metformin; Mitochondria; Oxygen Consumption; Pancreatic Neoplasms; Pyrazoles; Sulfonamides | 2014 |
Second-line treatment for pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Leucovorin; Metformin; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2014 |
Resistance to gemcitabine in the pancreatic cancer cell line KLM1-R reversed by metformin action.
Topics: Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Metformin; Molecular Chaperones; Pancreatic Neoplasms; Phosphorylation | 2015 |
Metformin Increases Sensitivity of Pancreatic Cancer Cells to Gemcitabine by Reducing CD133+ Cell Populations and Suppressing ERK/P70S6K Signaling.
Topics: AC133 Antigen; Animals; Antigens, CD; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Female; Gemcitabine; Gene Knockdown Techniques; Glycoproteins; Humans; Metformin; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplastic Stem Cells; Pancreatic Neoplasms; Peptides; Phosphorylation; Prognosis; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Xenograft Model Antitumor Assays | 2015 |
Intratumoral heterogeneity of the therapeutical response to gemcitabine and metformin.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Hydrogen-Ion Concentration; Male; Metformin; Mice; Mice, Inbred C57BL; Pancreatic Neoplasms; Pancreatic Stellate Cells; Tumor Burden; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2016 |
Inhibitory effect of metformin combined with gemcitabine on pancreatic cancer cells in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Humans; Hypoglycemic Agents; Metformin; Mice, Nude; Pancreas; Pancreatic Neoplasms | 2016 |
Desmoplasia suppression by metformin-mediated AMPK activation inhibits pancreatic cancer progression.
Topics: AMP-Activated Protein Kinases; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Coculture Techniques; Cytokines; Deoxycytidine; Disease Progression; Enzyme Activation; Enzyme Activators; Female; Fibrosis; Gemcitabine; Humans; Metformin; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Pancreatic Neoplasms; Pancreatic Stellate Cells; Paracrine Communication; Phosphorylation; RNA Interference; Signal Transduction; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Metformin potentiates the anticancer activities of gemcitabine and cisplatin against cholangiocarcinoma cells in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bile Duct Neoplasms; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Male; Metformin; Mice; Mice, Inbred BALB C; Mice, Nude; Xenograft Model Antitumor Assays | 2016 |
Metformin-induced alterations in nucleotide metabolism cause 5-fluorouracil resistance but gemcitabine susceptibility in oesophageal squamous cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Drug Synergism; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Metformin; Mice; Thymidine Kinase; Thymidylate Synthase; Thymine Nucleotides; Up-Regulation; Xenograft Model Antitumor Assays | 2018 |
Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Homeodomain Proteins; Hypoglycemic Agents; Male; Metformin; Mice; Mice, Knockout; Mutation; Neovascularization, Pathologic; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Trans-Activators; Tumor Microenvironment; Tumor Suppressor Protein p53 | 2018 |
Mechanisms of metformin's anti‑tumor activity against gemcitabine‑resistant pancreatic adenocarcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Metformin; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2019 |
Mechanism of metformin enhancing the sensitivity of human pancreatic cancer cells to gem-citabine by regulating the PI3K/Akt/mTOR signaling pathway.
Topics: Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Metformin; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinase; Phosphorylation; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases; Tumor Stem Cell Assay | 2019 |
Metformin-Induced Stromal Depletion to Enhance the Penetration of Gemcitabine-Loaded Magnetic Nanoparticles for Pancreatic Cancer Targeted Therapy.
Topics: Adenocarcinoma; Amino Acid Sequence; Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Gemcitabine; Humans; Magnetite Nanoparticles; Male; Metformin; Mice, Inbred BALB C; Pancreatic Neoplasms; Pancreatic Stellate Cells; Peptides | 2020 |
GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals.
Topics: Adenocarcinoma; Adenylate Kinase; Antineoplastic Agents; bcl-X Protein; Berberine; Biphenyl Compounds; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Diabetes Mellitus; Dietary Supplements; Disease Progression; Doxorubicin; Female; Fluorouracil; Gemcitabine; Glycogen Synthase Kinase 3 beta; Glycolysis; Humans; Inhibitory Concentration 50; Malaria; MCF-7 Cells; Metformin; Molecular Targeted Therapy; Neoplasm Metastasis; Nitrophenols; Pancreatic Neoplasms; Piperazines; Protein Kinase Inhibitors; Signal Transduction; Sulfonamides; Thiadiazoles; Tumor Stem Cell Assay | 2021 |
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Diabetes Mellitus, Type 2; Female; Gemcitabine; Glucose; Humans; Hypoglycemic Agents; Immunity; Insulins; Male; Metformin; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2023 |